Navigation Links
Nano drug crosses blood-brain tumor barrier, targets brain-tumor cells and blood vessels

  • The blood-brain barrier protects the brain from poisons but also prevents drugs from reaching brain tumors; innovative new treatments are needed.
  • This laboratory study shows that a nanotechnology drug called SapC-DOPS crosses that barrier and targets brain-tumor cells and retards growth of tumor blood vessels.
  • The findings also show how the agent targets tumor cells and recommend its further development as a novel treatment for glioblastoma.

COLUMBUS, Ohio An experimental drug in early development for aggressive brain tumors can cross the blood-brain tumor barrier and kill tumor cells and block the growth of tumor blood vessels, according to a study led by researchers at the Ohio State University Comprehensive Cancer Center Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC James).

The laboratory and animal study also shows how the agent, called SapC-DOPS, targets tumor cells and blood vessels. The findings support further development of the drug as a novel treatment for brain tumors.

Glioblastoma multiforme is the most common and aggressive form of brain cancer, with a median survival of about 15 months. A major obstacle to improving treatment for the 3,470 cases of the disease expected in the United States this year is the blood-brain barrier, the name given to the tight fit of cells that make up the blood vessels in the brain. That barrier protects the brain from toxins in the blood but also keeps drugs in the bloodstream from reaching brain tumors.

"Few drugs have the capacity to cross the tumor blood-brain barrier and specifically target tumor cells," says principal investigator Balveen Kaur, PhD, associate professor of neurological surgery and chief of the Dardinger Laboratory of Neurosciences at the OSUCCC James. "Our preclinical study indicates that SapC-DOPS does both and inhibits the growth of new tumor blood vessels, suggesting that this agent could one day be an important treatment for glioblastoma and other solid tumors."

The findings were published in a recent issue of the journal Molecular Therapy.

SapC-DOPS (saposin-C dioleoylphosphatidylserine), is a nanovesicle drug that has shown activity in glioblastoma, pancreatic cancer and other solid tumors in preclinical studies. The nanovesicles fuse with tumor cells, causing them to self-destruct by apoptosis.

Key findings of the study, which used two brain-tumor models, include:

  • SapC-DOPS binds with exposed patches of the phospholipid phosphatidylserine (PtdSer) on the surface of tumor cells;
  • Blocking PtdSer on cells inhibited tumor targeting;
  • SapC-DOPS strongly inhibited brain-tumor blood-vessel growth in cell and animal models, probably because these cells also have high levels of exposed PtdSer.
  • Hypoxic cells were sensitized to killing by SapC-DOPS.

"Based on our findings, we speculate that SapC-DOPS could have a synergistic effect when combined with chemotherapy or radiation therapy, both of which are known to increase the levels of exposed PtdSer on cancer cells," Kaur says.


Contact: Darrell E. Ward
Ohio State University Medical Center

Related medicine news :

1. A new European network crosses the boundaries for excellence in language and perception research
2. E-Store India Crosses the 1-million Mark for Number of Registered Online Buyers
3. Nano-devices that cross blood-brain barrier open door to treatment of cerebral palsy
4. Improved Stem Cell Line May Avoid Tumor Risk: Study
5. Normalizing tumor blood vessels improves delivery of only the smallest nanomedicines
6. Dental X-Rays May Be Linked to Benign Brain Tumors
7. Live imaging shows response to cancer drugs can be boosted by altering tumor microenvironment
8. Brain Tumor Vaccine Shows Promise in Early Trial
9. Kidney Cancer Patients Fare Better With Tumor Removal Only
10. IBN discovers human neural stem cells with tumor targeting ability
11. Protein prevents DNA damage in the developing brain and might serve as a tumor suppressor
Post Your Comments:
(Date:10/13/2015)... ... October 13, 2015 , ... Vision Group Holdings, the largest LASIK provider in ... brands including The LASIK Vision Institute and TLC Laser Eye Centers, Vision Group Holdings ... laser vision correction. , Global Laser Vision will continue to operate in San Diego ...
(Date:10/13/2015)... ... October 13, 2015 , ... PhyMed Healthcare Group ... announced its partnership with WPC Healthcare , a provider of predictive analytics ... the data into an aggregated data repository necessary to perform reporting and analytics ...
(Date:10/13/2015)... ... October 13, 2015 , ... Symposium Chairman, Dr. Rod J. ... Dallas Cosmetic Symposium to be held March 2nd and 3rd, 2016. The annual meeting, ... plastic surgeons and cosmetic physicians from around the world. , Key topics at this ...
(Date:10/13/2015)... ... October 13, 2015 , ... e-con Systems Inc., a leading embedded design ... the industry’s first RGB-IR pixel format camera with a USB 3.0 interface and ... See3CAM family of UVC USB 3.0 cameras, is based on the 1/3-inch OV4682 - ...
(Date:10/13/2015)... ... October 13, 2015 , ... ... today their Title Sponsorship of Synergy 2015. The annual WennSoft KEY2ACT user conference ... Valley Ranch and will unite customers, partners, WennSoft team members and sponsors to ...
Breaking Medicine News(10 mins):
(Date:10/13/2015)... 13, 2015  Vitamin Angels – a charity that ... need of nutritional support - announced its work continues ... Nations (UN). The UN,s newly established Global Goals - ... recent follow up to the Millennium Development Goals established ... The new 17 Global Goals intend to address three ...
(Date:10/13/2015)... Generational Equity , a leading mergers and acquisitions advisor ... acquisition of its client, Quality Medical Rentals ... by Meridian Biomedical, Inc. (Meridian), headquartered in Colorado.  The ... Florida . To learn more, visit ... To learn more, visit . --> ...
(Date:10/13/2015)... -- The spine division of Zimmer Biomet (NYSE and SIX: ... its portfolio of innovative clinical solutions and technologies at ... 14-17, 2015, in Chicago , Illinois.  ... "Supplemental MIS Fixation Options for LLIF" NASS ... 1 p.m. --> "Supplemental MIS Fixation Options ...
Breaking Medicine Technology: